According to a new research report “Global T-Cell Immunotherapy Pipeline Analysis, 2016 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Intelligence, the T cell immunotherapy exhibits strong pipeline with estimated 139 drug candidates in 2016.
T-cell immunotherapy pipeline in 2016
The study analyzed that the T-cell immunotherapy pipeline comprised of 139 therapeutic candidates in different stages of development. The high prevalence of cancer across the globe fuels the extensive research and development for the T-cell immunotherapeutic. T-cell immunotherapy is emerging as novel and promising approach for the treatment of cancer. It is gaining huge traction globally, for its several advantages over conventional therapies such as very low or no side effects and high specificity.
Browse the Report Summary at: https://www.psmarketresearch.com/market-analysis/t-cell-immunotherapy-pipeline-analysis
Chimeric antigen receptors (CAR) T-cell is majorly researched and developed, representing 75% T-cell immunotherapeutic candidates
CAR T-cells are the modified T-cells used to express CARs, which recognize specific antigens present on targeted cell. CARs are specifically designed synthetic receptors, linked with the single-chain variable fragment (scFV) of a monoclonal antibody. The domain includes T-cell receptor CD3-zeta chain, which graft specificity into an immune effector cell. It mediates T-cell cytotoxicity and activation when bound to a target cell.
Strategic collaborations for the development of T-cell immunotherapeutic
The research finds that the different companies are collaborating for the development of T-cell immunotherapeutic. In June 2015, Celgene Corporation and Juno Therapeutics, Inc. collaborated for the development and commercialization of immunotherapies.
Some of the key players developing T-cell immunotherapies are Novartis AG, Cellular Biomedicine Group, Inc., Kite Pharmaceuticals Inc. and others.
T-cell Immunotherapy Pipeline Analysis